223 related articles for article (PubMed ID: 16921451)
1. Usefulness of (18)F-fluorodeoxyglucose PET for radiosurgery planning and response monitoring in patients with recurrent spinal metastasis.
Gwak HS; Youn SM; Chang U; Lee DH; Cheon GJ; Rhee CH; Kim K; Kim HJ
Minim Invasive Neurosurg; 2006 Jun; 49(3):127-34. PubMed ID: 16921451
[TBL] [Abstract][Full Text] [Related]
2. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning.
Coon D; Gokhale AS; Burton SA; Heron DE; Ozhasoglu C; Christie N
Clin Lung Cancer; 2008 Jul; 9(4):217-21. PubMed ID: 18650169
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated stereotactic radiation therapy for skull base and upper cervical chordoma and chondrosarcoma: preliminary results.
Gwak HS; Yoo HJ; Youn SM; Chang U; Lee DH; Yoo SY; Rhee CH
Stereotact Funct Neurosurg; 2005; 83(5-6):233-43. PubMed ID: 16601376
[TBL] [Abstract][Full Text] [Related]
4. CyberKnife stereotactic radiotherapy for spinal tumors: value of computed tomographic myelography in spinal cord delineation.
Thariat J; Castelli J; Chanalet S; Marcie S; Mammar H; Bondiau PY
Neurosurgery; 2009 Feb; 64(2 Suppl):A60-6. PubMed ID: 19165075
[TBL] [Abstract][Full Text] [Related]
5. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases.
Stinauer MA; Diot Q; Westerly DC; Schefter TE; Kavanagh BD
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e613-8. PubMed ID: 22494588
[TBL] [Abstract][Full Text] [Related]
6. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
Specht JM; Tam SL; Kurland BF; Gralow JR; Livingston RB; Linden HM; Ellis GK; Schubert EK; Dunnwald LK; Mankoff DA
Breast Cancer Res Treat; 2007 Sep; 105(1):87-94. PubMed ID: 17268819
[TBL] [Abstract][Full Text] [Related]
7. FDG PET/MRI Coregistration Helps Predict Response to Gamma Knife Radiosurgery in Patients With Brain Metastases.
Leiva-Salinas C; Muttikkal TJE; Flors L; Puig J; Wintermark M; Patrie JT; Rehm PK; Sheehan JP; Schiff D
AJR Am J Roentgenol; 2019 Feb; 212(2):425-430. PubMed ID: 30422717
[TBL] [Abstract][Full Text] [Related]
8. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT.
Torigian DA; Lopez RF; Alapati S; Bodapati G; Hofheinz F; van den Hoff J; Saboury B; Alavi A
Hell J Nucl Med; 2011; 14(1):8-14. PubMed ID: 21512658
[TBL] [Abstract][Full Text] [Related]
10. Inferior glucose metabolism and chemosensitivity of post-radiotherapy local recurrence in comparison with distant metastases as assessed by sequential (18)F-FDG PET/CT imaging.
Sun X; Zhao F; Sun L; Li S; Li W; Zhang X; Xing L
Ann Nucl Med; 2014 Aug; 28(7):610-6. PubMed ID: 24838784
[TBL] [Abstract][Full Text] [Related]
11. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
12. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.
Satoh Y; Nambu A; Onishi H; Sawada E; Tominaga L; Kuriyama K; Komiyama T; Marino K; Aoki S; Araya M; Saito R; Maehata Y; Oguri M; Araki T
Eur J Radiol; 2012 Nov; 81(11):3530-4. PubMed ID: 22178287
[TBL] [Abstract][Full Text] [Related]
13. Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible?
Tsuyuguchi N; Sunada I; Iwai Y; Yamanaka K; Tanaka K; Takami T; Otsuka Y; Sakamoto S; Ohata K; Goto T; Hara M
J Neurosurg; 2003 May; 98(5):1056-64. PubMed ID: 12744366
[TBL] [Abstract][Full Text] [Related]
14. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
Ashamalla H; Rafla S; Parikh K; Mokhtar B; Goswami G; Kambam S; Abdel-Dayem H; Guirguis A; Ross P; Evola A
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1016-23. PubMed ID: 15979817
[TBL] [Abstract][Full Text] [Related]
15. Influence of FDG-PET on computed tomography-based radiotherapy planning for locally recurrent nasopharyngeal carcinoma.
Zheng XK; Chen LH; Wang QS; Wu HB; Wang HM; Chen YQ; Yan WP; Li QS; Xu YK
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1381-8. PubMed ID: 17869450
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
17. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results.
Okuma T; Okamura T; Matsuoka T; Yamamoto A; Oyama Y; Toyoshima M; Koyama K; Inoue K; Nakamura K; Inoue Y
Ann Nucl Med; 2006 Feb; 20(2):115-21. PubMed ID: 16615420
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous [18F]FDG-PET/MRI: Correlation of Apparent Diffusion Coefficient (ADC) and Standardized Uptake Value (SUV) in Primary and Recurrent Cervical Cancer.
Brandmaier P; Purz S; Bremicker K; Höckel M; Barthel H; Kluge R; Kahn T; Sabri O; Stumpp P
PLoS One; 2015; 10(11):e0141684. PubMed ID: 26551527
[TBL] [Abstract][Full Text] [Related]
19. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
[TBL] [Abstract][Full Text] [Related]
20. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
